Eastman Chemical to Acquire Genovique Specialties

Eastman Chemical said on Wednesday it will acquire Genovique Specialties in a deal that will increase its footprint in the growing market for specialty plasticizers. Financial details of the transaction were not disclosed, but Eastman said it expected the deal to boost its full-year 2010 earnings.

The transaction was also announced by Arsenal Capital Partners, a New York-based private equity firm which owns Genovique Specialties.

Eastman said the acquisition will establish the company as a global leader in non-phthalate plasticizers. Plasticizers or dispersants are additives that increase the plasticity or fluidity of a material such as plastics, cement and concrete.

Genovique Specialties, including its manufacturing operations in Chestertown, Md., Estonia, and a joint venture in Wuhan, China, will become part of Eastman's Performance Chemicals and Intermediates segment.

 

Company

Eastman Chemical Company

200 South Wilcox Drive
37662 Kingsport

Company contact







Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

most read

Photo
22.04.2025 • News

BASF Divests Two Joint Ventures in China

BASF has divested its shares in the joint venture companies, BASF Markor Chemical Manufacturing (Xinjiang) Co., Ltd. and Markor Meiou Chemical (Xinjiang) Co., Ltd. in Korla, China, to Verde Chemical Singapore Pte. Ltd.

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.